Streetbeat News

Products Services

NBIX

Neurocrine Biosciences announced positive top-line results from its Phase 2 clinical study of NBI-1117568, a treatment for adults with schizophrenia. This development could impact the company's stock positively.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:09 am

FFIV

INTC

F5 has partnered with Intel to enhance application security and delivery for AI deployments. The collaboration integrates F5's NGINX Plus with Intel's OpenVINO toolkit and IPUs, aiming to improve protection, scalability, and performance for AI inference.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:07 am

AVIR

Atea Pharmaceuticals published new data on the metabolic activation pathway of bemnifosbuvir, an antiviral in development for COVID-19 and HCV treatment.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:07 am

NRSN

NeuroSense Therapeutics is in advanced discussions with several major pharmaceutical companies for a strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for ALS treatment.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:02 am

NRSN

NeuroSense Therapeutics is in advanced talks with several large pharmaceutical companies for a strategic partnership to develop and commercialize its lead drug, PrimeC, for ALS. The discussions could lead to significant financial benefits for NeuroSense, though no definitive agreement has been reached yet.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 11:00 am

NVS

Novartis Pharma AG, a subsidiary of Novartis, has entered into a global licensing agreement and strategic collaboration with Lindy Biosciences to innovate in multi-target drug delivery.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 11:00 am

IYE

XLE

XOM

Exxon Mobil plans to sell $1 billion worth of conventional oil assets in the Permian Basin to focus on shale production after acquiring Pioneer Natural Resources. The company aims to produce 4.3 million barrels of oil and gas daily this year. Investors can gain exposure to Exxon Mobil through ETFs like XLE and IYE.

Portfolio Pulse from Lekha Gupta

August 28, 2024 | 10:43 am

SWTX

SpringWorks' Mirdametinib has received validation from the European Medicines Agency for treating NF1-PN in adults and children. The FDA has granted multiple designations, including Orphan Drug and Fast Track, indicating strong regulatory support.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:35 am

SWTX

SpringWorks Therapeutics announced that the FDA has accepted its New Drug Application for Mirdametinib, a treatment for Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, and granted it Priority Review with a PDUFA date set for February 28, 2025.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:33 am

OCGN

Ocugen has completed dosing in the third cohort of its Phase 1/2 GARDian clinical trial for OCU410ST, a gene therapy candidate for Stargardt disease.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 10:32 am